Observational studyAdvances in therapy2025
Real-World Insights on Satisfaction and Experience with Acthar Gel via SelfJect (RISE™): A Cross-Sectional Patient Survey.
Observational study in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionActhar
methodsReal-World Insights on Patient Satisfaction and Experience with Acthar Gel via SelfJect (RISE™) gathered responses via a non-interventional, observational, cross-sectional online survey with a pre-specified protocol (November 2024-January 2025). Eligible participants were aged ≥18 years, had a diagnosis of an indication of Acthar Gel based on the prescribing information, and had used Acthar Gel via SelfJect for ≥6 self-injections during the survey.
resultsFifty-four participants completed the survey (mean age 55.4 years, 76% women). Thirty-three percent (18/54) had chronic or recurring ocular inflammatory disease, and 26% (14/54) had rheumatoid arthritis. Thirty-nine percent (21/54) reported dexterity or visual problems, and 39% (21/54) had prior experience with Acthar Gel multi-dose vial. On average, administering Acthar Gel via SelfJect took 3.4 min. Overall, 91% (49/54) of participants reported that they were satisfied or very satisfied with Acthar Gel via SelfJect; 89% (48/54) felt very or extremely confident injecting with Acthar Gel via SelfJect; and 91% (49/54) found it to be convenient or very convenient. Seventy-six percent (41/54) felt that it was very or extremely easy to self-inject with this device. Eighty-seven percent (47/54) perceived that they were likely or very likely to maintain persistence and compliance with this device.
conclusionsSurvey participants reported a favorable experience with Acthar Gel via SelfJect, with a high level of satisfaction, confidence, convenience, and ease of use. Participants reported perceptions of anticipated positive persistence and compliance with this device, which may correlate with the possibility of improved continuity of care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.